Paul Bisaro Biography and Net Worth

Director of Zoetis

Mr. Bisaro provides exceptional global healthcare and pharmaceutical industry expertise from his prior senior executive leadership roles, including as President and CEO of Actavis and Executive Chairman of Allergan, with deep knowledge of manufacturing processes, R&D, product liability and regulatory matters. He also contributes valuable strategic M&A acumen to the Board, supporting discussions on identifying potential growth opportunities and market expansion possibilities. His legal background as a former public company general counsel, combined with extensive public company board experience, contributes strong legal and governance expertise to the Board.

What is Paul Bisaro's net worth?: The estimated net worth of Paul Bisaro is at least $2.11 million as of May 13th, 2026. Bisaro owns 27,862 shares of Zoetis stock worth more than $2,105,559 as of May 14th. This net worth estimate does not reflect any other investments that Bisaro may own. Learn More about Paul Bisaro's net worth.
How do I contact Paul Bisaro?: The corporate mailing address for Bisaro and other Zoetis executives is 10 Sylvan Way, Parsippany NJ, 07054. Zoetis can also be reached via phone at (973) 822-7000 and via email at [email protected]. Learn More on Paul Bisaro's contact information.
Has Paul Bisaro been buying or selling shares of Zoetis?: During the last quarter, Paul Bisaro has bought $151,760.00 of Zoetis stock. Most recently, on Wednesday, May 13th, Paul Bisaro bought 2,000 shares of Zoetis stock. The stock was acquired at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the transaction, the director now directly owns 27,862 shares of the company's stock, valued at $2,114,168.56. Learn More on Paul Bisaro's trading history.
Who are Zoetis' active insiders?: Zoetis' insider roster includes Juan Alaix (Director), Paul Bisaro (Director), Heidi Chen (EVP), Glenn David (EVP), Andrew Fenton (EVP), Wetteny Joseph (Exec. VP & CFO ), Robert Kelly (EVP), Catherine Knupp (EVP), Roxanne Lagano (EVP), Clinton Lewis, Jr. (EVP), Michael Mccallister (Director), Gregory Norden (Director), Kristin Peck (CEO & Director), Robert Polzer (EVP), Willie Reed (Director), Linda Rhodes (Director), Robert Scully (Director), and Roman Trawicki (EVP). Learn More on Zoetis' active insiders.
Are insiders buying or selling shares of Zoetis?: In the last twelve months, Zoetis insiders bought shares 3 times. They purchased a total of 11,650 shares worth more than $886,383.50. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 652 shares worth more than $110,840.00. The most recent insider tranaction occured on May, 13th when Director Frank A Damelio bought 6,650 shares worth more than $501,343.50. Insiders at Zoetis own 0.2% of the company. Learn More about insider trades at Zoetis.
Information on this page was last updated on 5/13/2026.

Paul Bisaro Insider Trading History at Zoetis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/13/2026	Buy	2,000	$75.88	$151,760.00	27,862

Paul Bisaro Buying and Selling Activity at Zoetis

Zoetis Company Overview

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

Today's Range

Now: $75.57

$73.98

$75.75

50 Day Range

MA: $114.33

$74.32

$126.06

2 Week Range

Now: $75.57

$73.98

$172.23

Volume

8,713,229 shs

Average Volume

5,012,589 shs

Market Capitalization

$31.68 billion

P/E Ratio

12.53

Dividend Yield

2.76%

Beta

0.87